| Literature DB >> 15780726 |
Edda Sciutto1, Andrea Toledo, Carmen Cruz, Gabriela Rosas, Gabriela Meneses, Diego Laplagne, Natalia Ainciart, Jacquelynne Cervantes, Gladis Fragoso, Fernando A Goldbaum.
Abstract
Lumazine synthase from Brucella spp. (BLS) was evaluated as a protein carrier to improve antigen delivery of KETc1, one of the peptides of the anti-cysticercosis vaccine. KETc1 becomes antigenic, preserved its immunogenicity and its protective capacity when expressed as a recombinant chimeric protein using Brucella spp. lumazine synthase. KETc1 and BLS-KETc1 were not MHC H-2(d), H-2(k) nor H-2(b) haplotype-restricted albeit KETc1 is preferentially presented in the H-2(b) haplotype. These findings support that BLS is a potent new delivery system for the improvement of subunit vaccines.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15780726 DOI： 10.1016/j.vaccine.2004.11.043
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641